ADVM Adverum Biotechnologies Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADVM

Price (delayed)

$11.15

Market cap

$231.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.6

Enterprise value

$219.07M

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ...

Highlights
Adverum Biotechnologies's debt has decreased by 31% YoY
ADVM's EPS is up by 26% YoY and by 8% QoQ
Adverum Biotechnologies's equity has shrunk by 54% YoY and by 19% QoQ
The quick ratio has contracted by 32% YoY and by 4.8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://adverum.com
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of ADVM
Market
Shares outstanding
20.75M
Market cap
$231.42M
Enterprise value
$219.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
31.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.85
Earnings
Revenue
$3.6M
EBIT
-$118.24M
EBITDA
-$99.57M
Free cash flow
-$91.71M
Per share
EPS
-$11.6
Free cash flow per share
-$9.1
Book value per share
$8.26
Revenue per share
$0.36
TBVPS
$17.16
Balance sheet
Total assets
$173.01M
Total liabilities
$89.54M
Debt
$64.63M
Equity
$83.47M
Working capital
$77.86M
Liquidity
Debt to equity
0.77
Current ratio
4.13
Quick ratio
3.95
Net debt/EBITDA
0.12
Margins
EBITDA margin
-2,765.9%
Gross margin
100%
Net margin
-3,254.6%
Operating margin
-3,444.2%
Efficiency
Return on assets
-52.8%
Return on equity
-98.6%
Return on invested capital
-73.9%
Return on capital employed
-79.8%
Return on sales
-3,284.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADVM stock price

How has the Adverum Biotechnologies stock price performed over time
Intraday
-1.76%
1 week
-6.85%
1 month
-37.01%
1 year
22.54%
YTD
48.11%
QTD
-21.15%

Financial performance

How have Adverum Biotechnologies's revenue and profit performed over time
Revenue
$3.6M
Gross profit
$3.6M
Operating income
-$123.99M
Net income
-$117.17M
Gross margin
100%
Net margin
-3,254.6%
Adverum Biotechnologies's net income has increased by 24% YoY and by 7% QoQ
ADVM's operating income is up by 21% YoY and by 6% from the previous quarter
Adverum Biotechnologies's net margin has increased by 7% QoQ
Adverum Biotechnologies's operating margin has increased by 6% QoQ

Growth

What is Adverum Biotechnologies's growth rate over time

Valuation

What is Adverum Biotechnologies stock price valuation
P/E
N/A
P/B
1.35
P/S
31.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.85
ADVM's EPS is up by 26% YoY and by 8% QoQ
Adverum Biotechnologies's equity has shrunk by 54% YoY and by 19% QoQ
The price to book (P/B) is 35% higher than the last 4 quarters average of 1.0 but 25% lower than the 5-year quarterly average of 1.8
The P/S is 2.1% below the last 4 quarters average of 31.9

Efficiency

How efficient is Adverum Biotechnologies business performance
Adverum Biotechnologies's return on invested capital has shrunk by 62% YoY and by 18% QoQ
Adverum Biotechnologies's return on equity has decreased by 46% YoY and by 12% QoQ
The company's return on assets fell by 22% YoY and by 7% QoQ
ADVM's ROS is up by 6% QoQ

Dividends

What is ADVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADVM.

Financial health

How did Adverum Biotechnologies financials performed over time
The total assets is 93% greater than the total liabilities
The total assets has declined by 44% year-on-year and by 12% since the previous quarter
The quick ratio has contracted by 32% YoY and by 4.8% from the previous quarter
Adverum Biotechnologies's debt is 23% lower than its equity
Adverum Biotechnologies's equity has shrunk by 54% YoY and by 19% QoQ
Adverum Biotechnologies's debt to equity has increased by 48% YoY and by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.